0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast to 2030- Product Image
Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast to 2030- Product Image
Sale

Chronic Inflammatory Demyelinating Polyneuropathy Market by Treatment Modality, End User, Distribution Channel, Patient Age, Disease Severity - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967535
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market stands at a critical juncture, presenting senior leaders with real opportunities for strategic differentiation amid complex clinical, regulatory, and supply chain dynamics. A layered landscape of innovation, shifting policies, and global disparities is changing the terms of competition, requiring renewed clarity and foresight for effective navigation.

Market Snapshot: Chronic Inflammatory Demyelinating Polyneuropathy Market Performance

The Chronic Inflammatory Demyelinating Polyneuropathy market grew from USD 2.49 billion in 2024 to USD 2.64 billion in 2025. Growth is projected to continue at a CAGR of 5.83%, with the market anticipated to reach USD 3.50 billion by 2030. These figures underscore expanding therapeutic demand, fueled by new biologics and evolving reimbursement strategies across both developed and emerging markets.

Scope & Segmentation

This research comprehensively covers treatment modalities, patient populations, healthcare channels, and regional demand variations. The structured segmentation is as follows:

  • Treatment Modality: Corticosteroids, Immunosuppressants (Azathioprine, Cyclophosphamide, Mycophenolate Mofetil, Rituximab), Intravenous Immunoglobulin, Plasma Exchange, Subcutaneous Immunoglobulin
  • End User: Home care, Hospitals, Specialty Clinics
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Patient Age: Adult, Geriatric, Pediatric
  • Disease Severity: Mild, Moderate, Severe
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Companies Profiled: Grifols, S.A.; CSL Behring AG; Octapharma AG; Takeda Pharmaceutical Company Limited; Baxter International Inc.; LFB S.A.; Kedrion S.p.A.; Biotest AG; Kamada Ltd.; Shanghai RAAS Blood Products Co., Ltd.

Key Takeaways: Strategic Insights for Decision-Makers

  • Emerging therapies, especially biologics and biosimilars, are reshaping traditional CIDP treatment, driving higher expectations for personalized approaches and improved patient outcomes.
  • Barriers such as diagnosis delays and reimbursement constraints continue to challenge optimal care, emphasizing the need for cross-stakeholder collaboration among neurology, immunology, and patient advocacy sectors.
  • Digital health solutions, including remote monitoring platforms and electronic registries, are increasingly integral in tracking disease progression and informing real-world evidence strategies.
  • Regional market disparities persist, with the Americas holding notable market share due to advanced infrastructure and stronger reimbursement environments, while Asia-Pacific registers high potential through local production and broader immunoglobulin access.
  • Strategic partnerships, particularly in manufacturing and supply chain resilience, are crucial to mitigating risks posed by global trade and policy shifts.
  • Portfolio diversification, incorporating diagnostics and next-generation therapies, supports sustained growth and competitive positioning.

Tariff Impact: Implications for the CIDP Market Supply Chain

The implementation of United States tariffs in 2025 has influenced the supply chain for CIDP therapeutics, notably impacting costs related to biologic components and solvents. Pharmaceutical manufacturers have responded by revising procurement and inventory policies, increasing localization of production, and seeking diversification of supplier bases. Distribution networks have been restructured to ensure resilience, with hospitals and specialty clinics adjusting contracts and exploring alternative formulations to manage budget pressures. Payers have tightened formulary criteria, prompting increased use of outcomes-based contracting and stronger supplier-hospital collaboration.

Methodology & Data Sources

This report is based on a combination of primary interviews with neurologists, payers, industry leaders, and patient advocates, alongside thorough secondary research from journals, clinical registries, and company filings. Rigorous data triangulation and scenario analysis, including tariff influences, ensure actionable and reliable insights for strategic decision-making.

Why This Report Matters

  • Equips leaders with a holistic view of the CIDP market’s therapeutic, regulatory, and supply chain dynamics for sound investment or partnership decisions.
  • Supports strategy development for regional market entry or expansion by clarifying payer priorities and competitive shifts across segments.
  • Enables forward-looking planning through detailed trend analysis and evidence-driven forecasts, giving senior decision-makers an edge in resource allocation and service delivery.

Conclusion

Navigating the CIDP market requires agile, data-driven strategies that account for clinical innovation, policy change, and supply adaptation. This report offers clear direction for stakeholders to identify growth opportunities and overcome evolving market barriers.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment Modality
8.1. Introduction
8.2. Corticosteroids
8.3. Immunosuppressants
8.3.1. Azathioprine
8.3.2. Cyclophosphamide
8.3.3. Mycophenolate Mofetil
8.3.4. Rituximab
8.4. Intravenous Immunoglobulin
8.5. Plasma Exchange
8.6. Subcutaneous Immunoglobulin
9. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End User
9.1. Introduction
9.2. Home Care
9.3. Hospitals
9.4. Specialty Clinics
10. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Patient Age
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Disease Severity
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Americas Chronic Inflammatory Demyelinating Polyneuropathy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Grifols, S.A.
16.3.2. CSL Behring AG
16.3.3. Octapharma AG
16.3.4. Takeda Pharmaceutical Company Limited
16.3.5. Baxter International Inc.
16.3.6. LFB S.A.
16.3.7. Kedrion S.p.A.
16.3.8. Biotest AG
16.3.9. Kamada Ltd.
16.3.10. Shanghai RAAS Blood Products Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 48. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 49. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 52. CANADA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 84. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 85. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 86. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 90. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 91. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 96. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 97. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 102. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 103. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 104. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 107. ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 108. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 109. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 110. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 113. SPAIN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 114. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 115. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 132. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 144. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 145. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 146. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 149. QATAR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 150. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 151. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 152. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 155. FINLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 156. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 157. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 162. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 163. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 168. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 169. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 170. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 173. EGYPT CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 174. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 175. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 176. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 186. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 187. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 188. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 191. NORWAY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 192. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 193. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 194. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 197. POLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 198. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 199. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 211. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 212. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 213. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 216. CHINA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 217. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 218. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 219. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 222. INDIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 224. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 228. JAPAN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 247. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 248. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 249. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 252. THAILAND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES CHRONIC INFLAMMATORY DEMYELINATING P

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Inflammatory Demyelinating Polyneuropathy market report include:
  • Grifols, S.A.
  • CSL Behring AG
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Baxter International Inc.
  • LFB S.A.
  • Kedrion S.p.A.
  • Biotest AG
  • Kamada Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.5 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

2025 Global Forecast for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
EUR$950USDGBP
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025 - Product Image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
EUR$4,490USDGBP
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Insight, 2025 - Product Image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
EUR$1,250USDGBP
Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From
EUR$5,950USDGBP
Guillain-Barre Syndrome Global Market Report 2025 - Product Image

Guillain-Barre Syndrome Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
EUR$4,490USDGBP

About the CIDP Drug Market

The CIDP Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. CIDP Drugs are used to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder that affects the peripheral nervous system. CIDP Drugs are typically immunomodulatory agents, such as corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange. These drugs are used to reduce inflammation and improve nerve conduction. The CIDP Drug market is highly competitive, with several major players. Companies such as Pfizer, Merck, and Novartis are leading the market with their immunomodulatory agents. Other companies such as Biogen, Sanofi, and AbbVie are also active in the CIDP Drug market, offering a range of treatments for CIDP. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more